Investors' Chronicle

UBM started life as a newspaper company, and spent most of the last century building up its media and PR operations. But diversification is no longer the watchword. Three years ago, the company chose to concentrate on its global events business. The share price, and the special returns, show investors have benefited from that decision, but where does the investment case stand now? An acquisition-l...

On this week's Personal Finance Show the team is joined by Rachel Winter, investment manager at Killik & Co. They ask whether you should go for the new three-year NS&I Investment Guaranteed Growth Bond. Its interest rate of 2.2 per cent trumps everything on the high street but it is already lagging the rate of inflation. Should you invest anyway? The team also talks inflation-beating asset allocat...

IC editor John Hughman is joined by small companies guru Simon Thompson and companies editor Ian Smith to discuss why the Aim market remains a stockpicker's paradise, and why news of snap election could spell trouble for the FTSE 100. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a servi...

Graphene and the hype surrounding atomic chicken wireMark Robinson talks to Gareth Jones (CFO) and Jon Mabbitt (CEO) of Applied Graphene Materials about the realistic options open to investors a decade down the line after the development of the so-called wonder material. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportuni...

The North Sea, recruiters, Libor, but no mention of Brexit…Deputy companies editor Mark Robinson steps in for John Hughman in this week's look at the latest news and signals in equity markets. With news editor Emma Powell and natural resources writer Alex Newman. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. In...

Bringing doctor surgeries into the 21st century, with modern facilities and a wide range of services is going to coast billions of pounds. Ironically, it will save money because a hospital visit costs the NHS far more than a visit to a doctor’s surgery. Without further investment, the situation is likely to get worse because more and more people are living longer, and this is the age group that is...

In this week's show Monica Tepes, director of investment companies research at Cantor Fitzgerald, joins the personal finance team to explain how investment trusts focused on alternative assets can generate a high income. They also set out the asset allocation models and funds you should be using in a Lifetime Isa, and explain how a new tax allowance could help to cut inheritance tax bills. Investo...

Companies editor Ian Smith and the team discuss the week's takeover news, Imagination Technologies' Apple contract loss and RPC's bears. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times . Hosted on Acast. See acast.com/privacy for more information.

The subprime lender is delivering on the buy-and-build strategy it set out at admission to the main market two years ago. So why has its share price struggled? Its founder and chief executive, John van Kuffeler, discusses the group's growth, investment case and changing regulatory environment with the IC's companies editor Ian Smith. Investors' Chronicle has supported private investors in the UK f...

In this week's Personal Finance Show the team puts momentum investing under the microscope. Is it a good idea to buy winning stocks or is it a risky investment strategy? Deputy personal finance editor Kate Beioley talks to Rob Burgeman, investment manager at Brewin Dolphin and personal finance writer Emma Agyemang to weigh up the risks and rewards. The team also takes a look at two new high-income...

Editor John Hughman and guests discuss Brexit, corporate fines, ageing & more Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times . Hosted on Acast. See acast.com/privacy for more information.

With money rotating out of bonds and into equity markets, value investing is back in vogue. But what constitutes value? How can investors spot it? And what are the common pitfalls? In this special podcast, tips editor Algy Hall and deputy companies editor Mark Robinson walk through the key measures and metrics beloved of value investors, with a little help from two of the UK's top fund managers. P...

Aviva faces regulatory changes, such as the 2015 pensions freedom reforms. It has been on the M&A trail, through its takeover of rival Friends Life. And now, it has set its sights on disrupting the Asian life market. It's also been a decent long-term investment since a strategic shift in 2012. Cash generation is up, debt is down, and non-core businesses are gone. Financial services writer Emma Pow...

In this week's show the team consider how to pick a good fund manager, and highlight some examples. They also look at the risks and rewards of the Lifetime Isa, which is set to launch next month. They are joined by Darius McDermott, managing director at Chelsea Financial Services. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment...

Editor John Hughman and guests discuss Sky/Fox, drug developments and cognitive biases in our weekly podcast Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times . Hosted on Acast. See acast.com/privacy for more information.

Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewa...

In this week's show James Baxter, partner at Tideway Wealth, joins the team to look at which investment trusts have proved to be the most reliable dividend payers over the years. They also consider some changes to the requirements for UK Equity Income sector funds and highlight a tax allowance that is soon to disappear. Investors' Chronicle has supported private investors in the UK for over 160 ye...

IC editor John Hughman, news editor Emma Powell and companies editor Ian Smith discuss the week's big news, including the surge in M&A and continuing regulatory ructions in the telecoms and media industry. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times . H...

BT's (BT.A) chief executive, Gavin Patterson, is not the only FTSE 100 boss to have announced a profit warning since the start of 2017. Several high profile companies have been forced to restate guidance since the start of the year. So is this a side effect of the current macroeconomic instability or do investors need to be wary of company structural issues which pre-date Brexit-related turmoil? A...

The importance of nutrition in sporting success has created a big market for elite sports supplements. But is the market for amateur athletes big enough to support growth at Aim-listed group Science in Sport (SIS)? Megan Boxall talks to the group's chief executive, Stephen Moon. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment o...

In this week's show the personal team and Chris Dillow, Investors Chronicle's economist, look at how some tax changes announced in Wednesday's budget will affect savers and investors. They also look at how to pick a good equity income fund and the merits of holding shares in your employer. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding i...

IC editor John Hughman talks to Mark Robinson about why investors should position their portfolios for a surge in defence spending, plus the latest news and results with companies editor Ian Smith. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times . Hosted on...

The UK and US stock markets have hit record highs in 2017 but are investors kidding themselves that valuations are sustainable? Professor Robert Shiller, Nobel Prize winner and current president of the American Economic Association, is advocating more research into how investors pick the narratives that take hold and drive prices higher. In his interview with the IC's James Norrington, he discusse...

In this week's Isa special podcast Sarah Lord, board director of the Personal Finance Society, explains some of the ways you can use an Isa for your saving and investing goals. The IC personal finance team also explain what the different types of Isa are, and how you can buy one in the most cost effective way. Investors' Chronicle has supported private investors in the UK for over 160 years by hig...

Editor John Hughman and guests discuss a wide range of topics from insurance to pasties to Georgian rugby as well as all the main news and features in this week's magazine. Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times . Hosted on Acast. See acast.com/pri...